Jonathan Brammer is a Hematology physician affiliated with The Ohio State University Comprehensive Cancer Center. OpenAlex indexes 306 publications with 2,607 citations (h-index 24); ClinicalTrials.gov lists 5 registered studies matched to this name.
Overview
Scholarship
indexed output and impact (OpenAlex)Distinct works indexed by OpenAlex, matched via ORCID.
Total citations across indexed works.
Hirsch index, productivity × impact (OpenAlex).
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
460 W 10th Ave
Columbus, OH 432101240
Telephone
614-293-3196Provider last certified this registry record 26 Feb 2026.
Clinical trials
- Ruxolitinib Maintenance Post-Hematopoietic Stem Cell Transplant T-Cell Lymphoma
Sponsor: Jonathan Brammer
- Ruxolitinib for the Treatment of T-Cell Large Granular Lymphocytic Leukemia
Sponsor: Jonathan Brammer
Registered studies on ClinicalTrials.gov where the overall official or a site investigator name-matches this physician, confirmed against known institution/geography. Latest few shown; the full list is part of the full profile.
Industry payments
2 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- PFIZER INC.Program year20253 payments
- Seagen Inc.Program year20223 payments
- Seagen Inc.Program year20214 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
NIH funding
1 NIH research award on record, funded 2024–2025 per NIH RePORTER. The latest:
- Mechanisms of Resistance and Therapeutic Targets in T-LGL Leukemia
Ohio State University
FY2025$78,750R03CA286694 - Mechanisms of Resistance and Therapeutic Targets in T-LGL Leukemia
Ohio State University
FY2024$78,750R03CA286694
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Publications
Matched to this physician's OpenAlex author record; most-cited works shown first.
- Combination ruxolitinib and belumosudil is tolerable and induces responses despite treatment failure as monotherapies
Leukemia & lymphoma/Leukemia and lymphoma
2024
Similar KOLs
Other experts from the same institution or the same specialty.
Ricardo Carrau, MD
The Ohio State University Comprehensive Cancer Center
Gregory Otterson, MD
The Ohio State University Comprehensive Cancer Center
Steven Clinton, MD, PhD
The Ohio State University Comprehensive Cancer Center
Christian Rolfo, MD
The Ohio State University Comprehensive Cancer Center
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”